Spinal muscular atrophy

Global RNA Therapeutics Market Trends, Growth Drivers, and Growth Opportunities 2021-2022 & 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Genetics, Pharmaceutical, Health, Oligonucleotide, DNA, RNA, Therapy, COVID-19, CDMO, Cystic fibrosis, Research, Spinal muscular atrophy, MicroRNA, Technology transfer, Vaccine, Fine chemical

The "Global RNA Therapeutics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNA Therapeutics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This research service provides an overview of the global RNA therapeutics industry from 2021 to 2027, including emerging trends, growth drivers, and growth opportunities.
  • The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target "undruggable" pathways.
  • Technological advantages, coupled with the growing need to build clinically superior portfolios in RNA therapeutics for a competitive edge, are anticipated to drive strategic partnerships among stakeholders in the RNA therapeutics industry.

Gene Therapy Global Market Research Report 2022 by Gene Type (Antigen; Cytokine; Suicide Gene; Others) & Vector (Viral Vector; Non-Viral Vector) - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Health, Genetics, Prostate, Population, COVID-19, Spinal muscular atrophy, American Cancer Society, Degenerative disease, Intelligence, Female, Gene, Artificial intelligence, Vector, Lists of diseases, Cancer, Pressure, Hospital, Growth, Infection, Disease, National Health Service, RMIT University, Lung, Machine learning, Neoplasm, Cell death, Application, Texas Homecare, Organization, Voretigene neparvovec, AI, Breast cancer, Medical device, Pharmaceutical industry, Vaccine

The "Gene Therapy Global Market Report 2022: By Gene, By Vector, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gene Therapy Global Market Report 2022: By Gene, By Vector, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering.
  • The gene therapy market consists of sales of gene therapy related services by entities (organizations, sole traders and partnerships) that manufacture gene therapy drugs.
  • The main types of gene therapy are antigen, cytokine, suicide gene and others.
  • The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market.

Biophytis presents preclinical efficacy data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease

Retrieved on: 
Thursday, June 16, 2022
Degenerative disease, Duchenne, Review, Security (finance), Therapy, COVID-19, Spinal muscular atrophy, Ageing, Duchenne muscular dystrophy, CEO, American depositary receipt, Euronext Growth, Neurodegeneration, Company, U.S. Securities and Exchange Commission, Sarcopenia, Forward-looking statement, AMF, ADS, CET, SEC, Ticker, Death, Patient, Life, DMD, Pharmaceutical industry, SMA, Nasdaq

Stanislas Veillet, CEO of Biophytis, said: "We are very pleased to present this work to the SMA community.

Key Points: 
  • Stanislas Veillet, CEO of Biophytis, said: "We are very pleased to present this work to the SMA community.
  • These new data highlight the full potential of Sarconeos (BIO101) beyond age-related diseases (sarcopenia and COVID-19) for which it is in late stage clinical development.
  • Biophytis is currently preparing the start of the MYODA clinical program in the Duchenne Muscular Dystrophy for late 2022/early 2023."
  • SMA is a rare progressive neurodegenerative disease that robs an individual of the ability to walk, eat and breathe.

Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

Retrieved on: 
Thursday, June 16, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, PSEN2, Disease, University, RO, Duchenne muscular dystrophy, Conference, Banner, Neurotoxicity, Spinal muscular atrophy, Alzheimer's disease, University of Antioquia, Person, Brain, Biotechnology, Free, National Institute on Aging, API, Autosome, Mutation, Neuromyelitis optica spectrum disorder, NIH, ADAD, III, AAIC, Knowledge, BAI, Magnetic resonance imaging, Lists of diseases, Government budget balance, National Institute, Neuroscience, Patient, ROG, Diagnosis, Dementia, ARIA, Risk, Biomedical Research, Multiple sclerosis, NIA, Duchenne, Registry, PSEN1, Collaboration, Gantenerumab, Immunoglobulin G, Hoffmann-La Roche, Research, Crenezumab, GNA, Family, Roche, APP, MRI, Head, Pharmaceutical industry, Medical imaging, Ageing, Genentech

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimers Institute, today announced results from the Alzheimers Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), together with Banner Alzheimers Institute, today announced results from the Alzheimers Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial.
  • The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimers disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimers disease.
  • Within its Alzheimers pipeline, Genentech is also evaluating the potential of gantenerumab in autosomal dominant Alzheimers disease, as well as for the prevention of sporadic Alzheimers and treatment of early Alzheimers in late stage clinical trials.
  • The Alzheimers Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimers prevention research.

The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities

Retrieved on: 
Tuesday, June 14, 2022
Goal, Company, Biotechnology, Labs, ESG, Gaps, Peguero, Climate, Workforce, Access, RTP, STAR, Massachusetts General Hospital, Technology, COVID-19, Lists of diseases, Engineering, U.S. Securities and Exchange Commission, Ready schools, Lab, Northeastern University, Research Triangle Park, Food, North Carolina Science Festival, Technorama, Pathology, CEO, Meal, Health, Foundation, Neuroscience, MGH, Health equity, BIIB, Risk, Patient, Feeding America, Nobel Prize, Greater Boston Food Bank, Multiple sclerosis, Spinal muscular atrophy, Education, Food security, Private Securities Litigation Reform Act, Science, Boston Red Sox, Program, Curriculum, Research, News, Nasdaq, Student, GLOBE, Hospital, Neurology, Medicine, Tutoring, Management, Pharmaceutical industry, Biogen, STEM

In 2002, Biogen also established the first-ever corporate Community Lab in Cambridge, Mass., a free science education program for students in middle and high school.

Key Points: 
  • In 2002, Biogen also established the first-ever corporate Community Lab in Cambridge, Mass., a free science education program for students in middle and high school.
  • In looking to the future, the Company plans for a Biogen Community Lab 2.0, which will include an enhanced neuroscience curriculum, a newly founded alumni network, and expanded global reach.
  • Biogen will officially kick off this 20th anniversary together with the Red Sox Foundation , which the Biogen Foundation has supported since 2016.
  • For more than 20 years, Biogen and the Biogen Foundation have supported educational programs like the Red Sox Scholars and visionary initiatives like the Biogen Community Lab, one of the first and longest-running hands-on corporate science programs.

Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

Retrieved on: 
Thursday, June 9, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, FTD, Company, Conference, RPD, Review, COVID-19, Research, European Medicines Agency, Neuromuscular Disorders, Neurology, Cancer, U.S. Securities and Exchange Commission, SMA, Intellectual property, Rock, Food, CEO, Investor, ODD, Quality of life, Social media, Securities Act of 1933, Human, EMA, Johns Hopkins University, Webcast, Security (finance), Myostatin, Doctor of Pharmacy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, ID, Patient, Fast Track, Spinal muscular atrophy, Private Securities Litigation Reform Act, Fibrosis, LLC, Drug Quality and Security Act, FAQ, LinkedIn, Disease, TOPAZ, FDA, Growth, NASDAQ, Twitter, File, Clinical trial, Detail, Orphan drug, Safety, Pharmaceutical industry, Management, Gongshi, Pediatrics

Details of the podium presentations are as follows:

Key Points: 
  • Details of the podium presentations are as follows:
    Presenter: Hemal Shah, PharmD, an independent HEOR consultant for Scholar Rock, and CEO of Value Matters, LLC.
  • To participate in the call, please dial 833-519-1308 (domestic) or 914-800-3874 (international) and refer to conference ID: 6495684.
  • A webcast of the call will also be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
  • Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA.

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

Retrieved on: 
Monday, June 6, 2022
Science, Â, Neuroscience, Movement disorders, Intellectual property, Research, Biotechnology, LinkedIn, Alecto, Pathology, Standard of care, Neurodegeneration, News, CEO, Disease, YouTube, Failure, Climate, Nasdaq, Therapy, U.S. Securities and Exchange Commission, BIIB, GLOBE, Patient, Private Securities Litigation Reform Act, Risk, Health, COVID-19, Lists of diseases, Nobel Prize, GBA2, Social media, Twitter, Multiple sclerosis, PD, Spinal muscular atrophy, Safety, Pharmaceutical industry, Facebook, Biogen

and BURNABY, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) -- Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinsons disease (PD).

Key Points: 
  • and BURNABY, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) -- Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinsons disease (PD).
  • This collaboration combines Alectos expertise in small-molecule therapeutics with Biogens development capabilities in movement disorders.
  • Currently, there are no approved disease modifying therapies for PD, creating significant unmet needs for patients seeking to slow disease progression.
  • Alectos Therapeutics is a leader in the discovery and preclinical development of novel small-molecule therapeutics to treat neurological diseases.

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

Retrieved on: 
Monday, June 6, 2022
Science, Â, Collaboration, Neuroscience, Movement disorders, Intellectual property, Research, Biotechnology, LinkedIn, Alecto, Pathology, Standard of care, Neurodegeneration, News, CEO, Disease, YouTube, Failure, Climate, Potential, Nasdaq, Therapy, Novel, U.S. Securities and Exchange Commission, BIIB, GLOBE, Patient, Private Securities Litigation Reform Act, Risk, Health, COVID-19, Lists of diseases, Nobel Prize, GBA2, Social media, Twitter, Multiple sclerosis, PD, Spinal muscular atrophy, Safety, Pharmaceutical industry, Facebook, Biogen

and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinsons Disease

Key Points: 
  • and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinsons Disease
    Cambridge, Mass.
  • and Burnaby, British Columbia June 6, 2022 Biogen Inc. (Nasdaq: BIIB) Biogen and Alectos Therapeutics have entered into a license and collaboration agreement to develop and commercialize a novel preclinical selective GBA2 inhibitor, AL01811, which has first-in-class potential as an oral disease modifying treatment for patients with Parkinsons disease (PD).
  • Currently, there are no approved disease modifying therapies for PD, creating significant unmet needs for patients seeking to slow disease progression.
  • Alectos Therapeutics is a leader in the discovery and preclinical development of novel small-molecule therapeutics to treat neurological diseases.

Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States

Retrieved on: 
Thursday, June 2, 2022
Biotechnology, Retinal, Hematology, Failure, Climate, IOP, COVID-19, Lists of diseases, Macular edema, Drug development, U.S. Securities and Exchange Commission, Severe cognitive impairment, Intellectual property, Macular degeneration, Food, Pathology, Partnership, AMD, VEGF, Central retinal vein occlusion, Health, Biosimilar, Intravitreal injection, Social media, Gastroenterology, Patient, United Kingdom, Neuroscience, American Academy, Neovascularization, Senior, BIIB, Physician, Intraocular pressure, Endophthalmitis, Nobel Prize, Multiple sclerosis, Spinal muscular atrophy, Private Securities Litigation Reform Act, Science, Research, LinkedIn, Health care, News, YouTube, Nasdaq, Samsung, FDA, Endocrinology, GLOBE, Risk, Twitter, Safety, Pharmaceutical industry, Generic drug, Biogen, Ophthalmology, Facebook

and INCHEON, Korea, June 02, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis Co., Ltd. today announced that BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab)i has been launched in the United States.

Key Points: 
  • and INCHEON, Korea, June 02, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis Co., Ltd. today announced that BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab)i has been launched in the United States.
  • The launch of BYOOVIZ in the U.S. marks an important moment for patients, healthcare providers, payers, and the entire healthcare system.
  • BYOOVIZ is the first biosimilar launch in the U.S. under the Biogen and Samsung Bioepis partnership.
  • The Biogen and Samsung Bioepis commercialization agreement includes two ophthalmology biosimilar candidates, BYOOVIZ and SB15, a biosimilar candidate referencing EYLEA (aflibercept)v. Samsung Bioepis is responsible for development, regulatory registration, and manufacture of the products, while Biogen is responsible for commercialization.

Alpha Cognition Announces First Quarter 2022 Results and Company Update

Retrieved on: 
Tuesday, May 31, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, P-value, Memantine, Company, Disease, R, G&A, Research, Depreciation, Growth hacking, Amyotrophic lateral sclerosis, News, Transaction, File, Dementia, Advertising, Traumatic brain injury, OTC Markets Group, Concussion, USD, COVID-19, Failure, TSX, FDA, Neurodegeneration, Alzheimer's disease, Industry, Cognition, Spinal muscular atrophy, Terminology, Central nervous system, Safety, Technology, Donepezil, TSX Venture Exchange, NDA, ACOG, Acquisition, Rivastigmine, Growth, Patient safety, ALS, Pharmaceutical industry, Dietary supplement, Cryptocurrency

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results for the first quarter ended March 31, 2022.
  • "Alpha Cognition reported positive preclinical data with ALPHA-1062 intranasal for mTBI and ALPHA-0602 for ALS during the first quarter of 2022 and continued to build-out our experienced leadership team.
  • The Company also plans to meet with the FDA for the ALPHA-1062 intranasal for mTBI during the third quarter of 2022.
  • During the second quarter of 2022, the company met with FDA regarding the ALPHA-1062 program for mild-to-moderate Alzheimers Disease.